WO1998022103A1 - Raf kinase inhibitors - Google Patents

Raf kinase inhibitors Download PDF

Info

Publication number
WO1998022103A1
WO1998022103A1 PCT/GB1997/003102 GB9703102W WO9822103A1 WO 1998022103 A1 WO1998022103 A1 WO 1998022103A1 GB 9703102 W GB9703102 W GB 9703102W WO 9822103 A1 WO9822103 A1 WO 9822103A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylphenyl
cyclohexylpropionylamino
alkyl
acetoxybenzamide
hydroxybenzamide
Prior art date
Application number
PCT/GB1997/003102
Other languages
French (fr)
Inventor
Philip John Hedge
Francis Thomas Boyle
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Limited filed Critical Zeneca Limited
Priority to EP97912325A priority Critical patent/EP0941084A1/en
Priority to AU49562/97A priority patent/AU4956297A/en
Priority to CA002267782A priority patent/CA2267782A1/en
Priority to JP52331698A priority patent/JP2001504478A/en
Publication of WO1998022103A1 publication Critical patent/WO1998022103A1/en
Priority to NO992336A priority patent/NO992336D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Definitions

  • This invention relates to compounds that inhibit the enzyme raf kinase (raf), an enzyme which acts downstream of ras and plays a crucial role in transduction of signal towards the nucleus.
  • the invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through raf kinase activity.
  • Oncogenic forms of ras are found in 30% of all cancers, including colon (50%), lung (30%) and pancreas (90%). Mutated, oncogenic forms of the ras GTP-binding proteins are insensitive to activation of their intrinsic GTPase activity and therefore locked in an active form, constitutively activating downstream components of a mitogenic signalling pathway.
  • ras binds directly to the product of the raf proto-oncogene, c-raf-1, thus implicating raf as an effector of ras mediated signalling (Cell (1993) 74, 308-313).
  • Raf lies at the top of a kinase cascade which results in activation of MEK (Map kinase kinase) and then MAP-kinase and subsequent transcriptional activation of genes involved in cell proliferation.
  • MEK Map kinase kinase
  • MAP-kinase MAP-kinase and subsequent transcriptional activation of genes involved in cell proliferation.
  • Ras antisense has antitumour activity in human tumour mouse xenograft models
  • Specific cancers of interest include:
  • -carcinoma including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin;
  • lymphoid lineage including acute lymphocytic leukemia, B-cell lymphoma and Burketts lymphoma;
  • - hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias and promyelocytic leukemia; -tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; and
  • tumors including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.
  • Raf inhibitors may also be useful in the treatment of diseases other than cancer that may be associated with signal transduction pathways operating through Ras, e.g., neuro-fibromatosis.
  • composition comprising an inhibitor of raf kinase of the formula I wherein:
  • R 1 and R 2 which may be the same or different are selected from hydroxy, C,. 6 alkoxy, mercapto, C,. 6 alkylthio, amino, C
  • 6 alkyl hydroxyC ⁇ alkyl, aminoC
  • R 1 and R 2 which may take the same or different values for R 1 and R 2 , is 0-3, and when p is 2 or 3 each group may be the same or different;
  • R 3 is C M alkyl; q is 0-4;
  • R 4 is aryl or cycloalkyl wherein R 4 is optionally substituted with upto 3 substituents having any value defined for R 1 ; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically-acceptable carrier with the proviso that N-[5-(3-cyclohexyl- propionylamino)-2-methylphenyl]-4-hydroxybenzamide, N-[5-(3- cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide,
  • the first excluded compound is known as RPR 102359 and is described as upregulating LDL receptors by Brown et al in Atherosclerosis (1994) 109: 1 13-1 14.
  • the other excluded compounds are also described as upregulating LDL receptors by Brown et al in J. Med. Chem. (1996), 39(17): 3343-3356.
  • Aryl in the terms “aryl”, “arylC,_ 6 alkyl” and “arylC ⁇ -6 alkoxy” typically means phenyl or naphthyl, preferably phenyl.
  • “Heteroaryl” in the terms “heteroaryl” and “heteroarylC ⁇ alkyl” means an aromatic mono- or bicyclic 5-10 membered ring with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur.
  • Heterocyclyl in the terms “heterocyclyl” and “heterocyclylC
  • Examples of 'heterocyclyl' include pyrrolidinyl, morpholinyl, piperidinyl, dihydropyridinyl and dihydropyrimidinyl.
  • Cycloalkyl means a non-aromatic mono- or bicyclic 5-10 membered carbon ring. Examples of “cycloalkyl” include cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptyl and bicyclo[4.4.0]decyl.
  • Typical values for generic groups include: C, .6 alkoxy for example methoxy, C,. 6 alkylthio for example methylthio, C,. 6 alkylamino for example methylamino, di-(C,. 6 alkyl)amino for example dime hylamino, C ⁇ -6 alkoxycarbonyl for example methoxycarbonyl or ethoxycarbonyl, C, .6 aIkylcarbamoyl for example methylcarbamoyl, di- C,. 6 alkylcarbamoyl for example dimethylcarbamoyl,
  • C,. 6 aIkylsulphonyl for example methylsulphonyl, arylsulphonyl for example phenylsulphonyl, C,. 6 alkyIaminosulphonyl for example methylaminosulphonyl, di-(C, . calkyl)aminosulphonyl for example dimethylaminosulphonyl, cyanoC, .6 alkyl for example cyanomethyl, hydroxyC,_ 6 alkyl for example hydroxymethyl, aminoC, .6 alkyl for example aminoethyl, C,.
  • 6 alkanoylamino for example formamido and acetamido
  • C,_ 6 alkoxycarbonylamino for example methoxycarbonylamino
  • C,_ 6 alkanoyl for example formyl and acetyl
  • C,. 6 aIkanoyloxy for example acetoxy
  • C,. 6 alkyl for example methyl, ethyl, isopropyl or tert-butyl
  • halo for example fluoro, chloro or bromo
  • aryl for example phenyl, arylC,.
  • 6 alkyl for example benzyl, aryloxy for example phenoxy and arylC,. 6 aIkoxy for example benzyloxy.
  • Any ring in R 1 or R 2 may be optionally substituted, for example by upto 3 substituents.
  • Suitable substituents include hydrogen, hydroxy, C ⁇ alkoxy, mercapto, C ⁇ _ 6 alkylthio, amino, C
  • alkyl includes both straight-chain and branched-chain alkyl groups.
  • references to individual alkyl groups such as “propyl” are specific for the straight-chain version only and references to individual branched-chain alkyl groups such as “isopropyl” are specific for the branched-chain version only.
  • An analogous convention applies to other generic terms.
  • optically active or racemic forms by virtue of one or more asymmetric carbon atoms
  • the invention includes in its definition any such optically active or racemic form which possesses the property of inhibiting raf.
  • the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.
  • inhibitory properties against raf may be evaluated using the standard laboratory techniques referred to hereinafter.
  • R 1 Particular values for R 1 include hydroxy; hydroxyC,. 6 alkyl for example hydroxymethyl and hydroxyethyl; carboxy; carbamoyl; C
  • alkylamino for example methylamino, ethylamino and propylamino
  • di-(C,_ 6 alkyl)amino for example di-methylamino, di-ethylamino and N-ethyl-N-methylamino
  • C,. 6 alkoxycarbonyl for example methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl.
  • R 1 are hydroxy, amino, C,. 6 alkylamino, di-(C,_ 6 alkyl)amino, C,. 6 alkoxy and C ⁇ _ 6 alkoxycarbonyl; more preferably hydroxy, methylamino, ethylamino, propylamino, di-methylamino, di-ethylamino and N-ethyl-N-methylamino.
  • Preferred positions for substitution of R 1 into the phenyl ring indicated in Formula I are 3, 4 and/or 5; more preferably 3; 4; 3,4 or 3,5.
  • R 1 is selected from 4-hydroxy; 4-dimethylamino; 3-methoxy; 3,5-dimethoxy; 3-methoxycarbonyl; and 4-hydroxy-3 -methoxy: of these 4-hydroxy is most preferred.
  • R 2 is preferably hydrogen.
  • Preferred values for p in (R') p are 1-2, especially 1.
  • a preferred value for p in (R ) p is 0.
  • R 3 is preferably C,. 3 alkyl, more preferably methyl or ethyl and especially methyl.
  • R 4 is preferably aryl, more preferably phenyl, more preferably monosubstituted phenyl and especially monosubstituted phenyl in the meta position, preferably with an electron withdrawing substituent group.
  • Typical electron withdrawing groups include amino, C
  • R 1 and (CH 2 ) q -R 4 include: R 1 (CH 2 ) q -R 4
  • R 2 is preferably hydrogen and R 1 is preferably methyl.
  • an inhibitor of raf kinase of formula II is provided:
  • R 1 and R 2 which may be the same or different are selected from hydroxy, C,. 6 alkoxy, mercapto, C,. 6 alkylthio, amino, C, .6 alkylamino, di-(C,. 6 alkyl)amino. carboxy, C,_ 6 alkoxycarbonyl, carbamoyl, C,. 6 alkylcarbamoyl, di-C ⁇ alkylcarbamoyl, C,. 6 alkylsulphonyl, arylsulphonyl, C,. 6 alkylaminosulphonyl, di-(C l . 6 alkyl)aminosulphonyl, nitro, cyano, cyano C,.
  • R 5 is selected from hydroxy, C,. 6 alkoxy, mercapto, C,. 6 alkylthio, amino, C,. 6 alkylamino, di-(C,. 6 alkyl)amino, carboxy, C,. 5 alkoxycarbonyl, carbamoyl, C,_ 6 alkylcarbamoyl, di-C,. 6 alkylcarbamoyl, C,. 6 alkylsulphonyl, arylsulphonyl, C,. 6 alkylaminosulphonyl, di-(C,. 6 alkyl)aminosulphonyl, nitro, cyano, cyanoC,. 6 alkyl, hydroxyC,.
  • a preferred individual compound of the invention is N- ⁇ 5-
  • R 5 is preferably an electron withdrawing group.
  • Typical electron withdrawing groups include amino, C,. 6 alkylamino, di-(C l . 6 alkyl)amino, carboxy, C,. 6 alkylsulphonyl, arylsulphonyl, nitro, cyano, halo, and trifluoromethyl; of these amino, C,. 6 alkylamino, di-(C,. 6 alkyl)amino, nitro, cyano and halo are preferred; more preferably di-(C,.
  • prodrugs are known in the art.
  • prodrug derivatives see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in
  • In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include methoxymethyl and for hydroxy include acetyl.
  • pro-drugs include in vivo hydrolysable esters of a compound of the Formula I.
  • An in vivo hydrolysable ester of a compound of the Formula I containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid.
  • Suitable pharmaceutically-acceptable esters for carboxy include C ⁇ _ 6 alkoxymethyl esters for example methoxymethyl, C,_ 6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 _ 8 cycloalkoxycarbonyloxyC,.
  • alkyl esters for example 1-cyclohexylcarbonyloxyethyl
  • 1,3- dioxolan-2-ylmethyl esters for example 5-methyl-l,3-dioxolan-2-ylmefhyl
  • ⁇ alkoxycarbonyloxy ethyl esters for example 1 -methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • a suitable pharmaceutically-acceptable salt of the invention when the compound contains an acidic moiety is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • a compound of the Formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixir
  • compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
  • inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate
  • granulating and disintegrating agents such as corn starch or algenic acid
  • binding agents such as starch
  • lubricating agents
  • Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
  • the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti- oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
  • the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
  • Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening, flavouring and preservative agents. Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol. aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
  • a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable excipients include, for example, cocoa butter and polyethylene glycols.
  • Topical formulations such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.
  • compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 ⁇ m or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose.
  • the powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
  • Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
  • the size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
  • compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of raf kinase activity.
  • a daily dose in the range for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses.
  • lower doses will be administered when a parenteral route is employed.
  • a dose in the range for example, 0.5 mg to 30 mg per kg body weight will generally be used.
  • a dose in the range for example, 0.5 mg to 25 mg per kg body weight will be used.
  • Oral administration is however preferred, particularly in tablet form.
  • unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.
  • Compounds of this invention may be useful in combination with known anti-cancer and cytotoxic agents. If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate. Therefore in a further aspect, the present invention provides a compound of the
  • Formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body.
  • the present invention provides a compound of the Formula I or N-[5- (3 -cyclohexy lpropiony lamino)-2-methy lpheny 1] -4-hydroxybenzamide, N- [5 -(3 - cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexylacety lamino)-2-methylpheny 1] -4-acetoxybenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3- cyclohexylpropiony
  • the present invention provides a method of treating a disease or medical condition mediated by raf kinase which comprises administering to a warm-blooded animal an effective amount of a compound of the Formula I or excluded compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
  • the present invention also provides the use of a compound of the Formula I or excluded compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof in the preparation of a medicament for use in a disease condition mediated by raf kinase.
  • the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of raf kinase. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
  • the compounds of Formula I are especially useful in treatment of tumours having a high incidence of ras mutation, such as colon, lung, and pancreatic tumours. By the administration of a composition having one (or a combination) of the compounds of this invention, development of tumours in a mammalian host is reduced.
  • the present invention provides a compound of the Formula I or excluded compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof in the preparation of a medicament for treating cancer.
  • the present invention provides a process for preparing a compound of the Formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises: reacting a compound of the Formula III:
  • variable groups are as hereinbefore defined wherein any functional group is protected, if necessary, and: i. removing any protecting groups; ii. optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
  • a carbodiimide coupling reagent is used in the presence of an organic solvent (preferably an anhydrous polar aprotic organic solvent) at a non-extreme temperature, for example in the region -10 to 40°, typically ambient temperature of about 20°C.
  • an organic solvent preferably an anhydrous polar aprotic organic solvent
  • Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
  • Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • protecting groups are given below for the sake of convenience, in which "lower” as in, for example, lower alkyl signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.
  • a carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester- forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).
  • carboxy protecting groups include straight or branched chain C].
  • alkyl groups for example isopropyl, t-butyl; lower alkoxy lower alkyl groups (for example methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (for example 1 -methoxycarbonyloxyethyl, 1 -ethoxycarbonyloxy ethyl); aryl lower alkyl groups (for example benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for example trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)sily
  • carboxy protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis.
  • hydroxy protecting groups include lower alkyl groups
  • lower alkenyl groups for example allyl
  • lower alkanoyl groups for example acetyl
  • lower alkoxycarbonyl groups for example t-butoxycarbonyl
  • lower alkenyloxycarbonyl groups for example allyloxycarbonyl
  • aryl lower alkoxycarbonyl groups for example benzoyloxycarbonyl, rj-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl
  • tri lower alkylsilyl for example trimethylsilyl, t-butyldimethylsilyl
  • aryl lower alkyl for example benzyl
  • amino protecting groups include formyl, aralkyl groups (for example benzyl and substituted benzyl, p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl. and triphenylmethyl); di-p-anisylmethyl and furylmethyl groups; lower alkanoyl (for example acetyl); lower alkoxycarbonyl (for example t-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl lower alkoxycarbonyl groups (for example benzyloxycarbonyl, r methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl; trialkylsilyl (for example trimethylsilyl and t-butyldimethylsilyl); alkylidene (for example methylidene); benzylidene and substituted benzylidene groups.
  • Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as p-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as o-nitrobenzyloxycarbonyl.
  • groups such as p-nitrobenzyloxycarbonyl
  • hydrogenation for groups such as benzyl
  • photolytically for groups such as o-nitrobenzyloxycarbonyl.
  • the reader is referred to Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.
  • the reader is referred to Protective Groups in Organic Synthesis. 2nd Edition, by Green et al, published by John Wiley & Sons for general guidance on protecting groups.
  • the compound of Formula III may be prepared by reduction of the corresponding nitro compound of Formula V.
  • Typical reaction conditions include the use of ammonium formate in the presence of a catalyst (for example palladium on carbon) in the presence of an organic solvent (preferably a polar protic solvent), preferably with heating, for example to about 60°. Any functional groups are protected and deprotected as necessary.
  • a catalyst for example palladium on carbon
  • an organic solvent preferably a polar protic solvent
  • Formula Typical conditions include activating the carboxyl group of the compound of Formula VI for example by treatment with a halo reagent (for example oxalyl chloride) to form an acyl halide in an organic solvent at ambient temperature, then reacting the activated compound with the compound of Formula VII. Any functional groups are protected and deprotected as necessary.
  • a halo reagent for example oxalyl chloride
  • GST-MEK Tris- HC1 pH7.4, O.lmM Ethylene Glycol bis ( ⁇ -Aminoethylether)NNNN-Tetra-acetic Acid (EGTA), lmg/ml Bovine Serum Albumin (BSA), ImM sodium vanadate, 0.03% Brij-35, 0.1% ⁇ -mercaptoethanol.
  • EGTA Ethylene Glycol bis ( ⁇ -Aminoethylether)NNNN-Tetra-acetic Acid
  • BSA Bovine Serum Albumin
  • ImM sodium vanadate 0.03% Brij-35
  • 0.1% ⁇ -mercaptoethanol 0.1% ⁇ -mercaptoethanol.
  • Add lO ⁇ l of Mg Adenosine Triphosphate (ATP) mix 50mM Mg Acetate, 50 ⁇ M ATP,l ⁇ Ci ⁇ 33 P ATP.
  • ATP Mg Adeno
  • Mg ATP mix 50mM Mg acetate, 150uM ATP,l ⁇ Ci ⁇ 3 P ATP. Incubate at room temperature for 90 minutes. Stop the reaction by adding 50 ⁇ l 20% phosphoric acid. Capture onto P81 phosphocellulose paper (Whatman), wash in 0.5% phosphoric acid three times, dry and count by liquid scintillation.
  • the starting material was prepared as follows: A) Oxalyl chloride (0.5 ml) was added slowly to a stirred suspension of 4-acetoxybenzoic acid (1.09 g), dry dichloromethane (30 ml) and DMF (one drop). The mixture is stirred for two hours at ambient temperature. A solution of 2-methyl-5-nitroaniline (760 mg) and pyridine (2.0 ml) in dry dichloromethane was added over 15 minutes. The reaction mixture was stirred for a further 2 hours, washed with 5% aqueous acetic acid (2 x 25 ml), water (20 ml) and 5% aqueous sodium hydrogen carbonate solution. The organic extract was dried over magnesium sulphate, filtered and evaporated to dryness.
  • Example 2 The method of Example 1 was repeated using 3,4-dichlorophenylacetic acid (0.5 mmoles). The reaction mixture was evaporated and the residue taken up in ethyl acetate (4 ml), washed with 1M hydrochloric acid (3.0 ml) and water (3.0 ml). The ethyl acetate extract was evaporated to give the desired product, 132mg (68%), shown to be 92% pure by HPLC.
  • N-(5-Amino-2-methylphenyl)-4-hydroxybenzamide (85 mg) was added to a stirred solution of 3-dimethylaminobenzoic acid (89 mg) in dry DMF (0.5 ml) followed by a solution of 1 -(3 -dimethy laminopropyl)-3-ethylcarbodiimide hydrochloride (103 mg) in dry dichloromethane (3 ml) and 4-dimefhylaminopyridine (131 mg).
  • the reaction was stirred at ambient temperature under argon for 18 hours.
  • the reaction mixture was purified by MPLC on silica eluting in turn with 50%, 60% and 70% ethyl acetate in isohexane to give 17 mg (1 1%) of the title product.
  • Compound X the active ingredient being termed "Compound X"
  • Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
  • the aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.

Abstract

The present invention relates to pharmaceutical compositions comprising inhibitors of raf kinase of formula (I) wherein: R?1 and R2¿ are substituents on the phenyl rings; p, which may take the same or different values for R?1 and R2¿, is 0-3, and when p is 2 or 3 each group may be the same or different; R3 is C¿1-4?alkyl; q is 0-4; R?4¿ is aryl or cycloalkyl wherein R4 is optionally substituted with up to 3 substituents or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier with the proviso that N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide, N-[5-(3-cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3-phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4-cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2-cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]benzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide and N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide are excluded. Processes for their preparation and their use as therapeutic agents. A particular use is in cancer therapy.

Description

RAF KINASE INHIBITORS
This invention relates to compounds that inhibit the enzyme raf kinase (raf), an enzyme which acts downstream of ras and plays a crucial role in transduction of signal towards the nucleus. The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through raf kinase activity.
Oncogenic forms of ras are found in 30% of all cancers, including colon (50%), lung (30%) and pancreas (90%). Mutated, oncogenic forms of the ras GTP-binding proteins are insensitive to activation of their intrinsic GTPase activity and therefore locked in an active form, constitutively activating downstream components of a mitogenic signalling pathway. Several groups simultaneously demonstrated that ras binds directly to the product of the raf proto-oncogene, c-raf-1, thus implicating raf as an effector of ras mediated signalling (Cell (1993) 74, 308-313). Raf lies at the top of a kinase cascade which results in activation of MEK (Map kinase kinase) and then MAP-kinase and subsequent transcriptional activation of genes involved in cell proliferation. This, coupled with previous evidence that raf is an essential downstream component of ras signalling and is itself oncogenically transforming when in a constitutively active form, highlights raf as a critical effector of ras mediated transformation. Evidence that inhibition of raf will result in anti-tumour activity is set out in the following references.
1) Dominant-negative ras mutants block ras function and raf-1 activation by serum or TPA in NIH3T3 cells (Oncogene (1992) 7, 1867-1873).
2) Genetic evidence in Drosophila and C. elegans shows that raf is essential for ras stimulated differentiation (Nature (1993) 360, p600-603; Nature (1993) 363,
133-139).
3) Constitutively active mutants of MEK (the downstream target of raf) have been shown to transform NIH3T3 cells (Science (1994) 265, 966-970). Moreover, dominant negative mutants of MEK have been shown to reverse the tumourigenicity of ras transformed cell lines (Cell (1994) 77, 841-852). 4) PD098059, a selective inhibitor of MEK activation by raf and other MEK activators
(J. Biol. Chem. (1995) 270, 27489-27494) has been shown to block the MAP kinase pathway and reverse the transformation of at least some ras transformed cell lines (Proc. Natl. Acad. Sci. USA (1995) 92, 7686-7689). 5) Inhibition of raf function (through use of dominant negative raf or antisense to raf) blocks ras-induced growth or ras-induced reporter gene expression (Nature (1991) 349, 416- 428; Genes & Dev. (1992) 6, 545-556).
6) Ras antisense has antitumour activity in human tumour mouse xenograft models
(Nature Medicine (1996), 2, 668-675). Taken together, these findings indicate that raf is both a direct and major effector of ras function and as such inhibition of the kinase activity of raf is expected to have antitumour activity in at least a proportion of human tumours.
Specific cancers of interest include:
-carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin;
-hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B-cell lymphoma and Burketts lymphoma;
- hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia; -tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; and
- other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.
Raf inhibitors may also be useful in the treatment of diseases other than cancer that may be associated with signal transduction pathways operating through Ras, e.g., neuro-fibromatosis.
According to one aspect of the present invention there is provided a pharmaceutical composition comprising an inhibitor of raf kinase of the formula I
Figure imgf000005_0001
wherein:
R1 and R2, which may be the same or different are selected from hydroxy, C,.6alkoxy, mercapto, C,.6alkylthio, amino, C|_6alkylamino, di-(C,.6alkyl)amino, carboxy, C,_6alkoxycarbonyl, carbamoyl, C,_6alkylcarbamoyl, di-C,.6alkylcarbamoyl, C,_6alkylsulphonyl, arylsulphonyl, C,.6alkylaminosulphonyl, di-(C,.6alkyl)aminosulphonyl, nitro, cyano, cyanoC|.6alkyl, hydroxyC^alkyl, aminoC|_6alkyl, C,.6alkanoylamino, C|.6alkoxycarbonylamino, C,.6alkanoyl, C,.6alkanoyloxy, C,_6alkyl, halo, trifluoromethyl, aryl, arylC,.6alkyl, arylC,.6alkoxy, heteroaryl, heteroarylC,.6alkyl, heterocyclyl and heterocyclylC^alkyl; p, which may take the same or different values for R1 and R2, is 0-3, and when p is 2 or 3 each group may be the same or different; R3 is CM alkyl; q is 0-4; R4 is aryl or cycloalkyl wherein R4 is optionally substituted with upto 3 substituents having any value defined for R1 ; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically-acceptable carrier with the proviso that N-[5-(3-cyclohexyl- propionylamino)-2-methylphenyl]-4-hydroxybenzamide, N-[5-(3- cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexy lacety lamino)-2-methy lphenyl] -4-acetoxybenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide. N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]benzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide, are excluded.
The first excluded compound is known as RPR 102359 and is described as upregulating LDL receptors by Brown et al in Atherosclerosis (1994) 109: 1 13-1 14. The other excluded compounds are also described as upregulating LDL receptors by Brown et al in J. Med. Chem. (1996), 39(17): 3343-3356.
Other compounds within the scope of Formula I are known outside the pharmaceutical field from: Japanese patent 62198852, Nozue et al, Japan Synthetic Rubber Company, Positive-type radiation resist composition; US patent 4410681, Prindle, Dow Chemical Company, Epoxy resins cured with salicyloyl hydrocarbylamines; US patent 4367328, Bertram et al, Dow Chemical Company, Epoxy resins from hydroxybenzamides; Japanese patent JP 53079835, Tanaka et al, Hitachi Limited, Dialkylaminoethyl trimellitate epoxy resin hardeners; German patent DE 2552609, Salle et al, Institut Francais du Petrole, Aromatic diester diamides; Japanese patent JP 50105558, Kubota et al, Adeka Argus Chemical Company, Polymers, hydrocarbon oils and rubbers resistant to metal induced degradation; Japanese patent JP 61204221, Nishizawa et al, Hitachi Chemical Company, Compatible thermosetting epoxy resin compositions; Netherlands patent application 6514411, J R Geigy, Heterocyclic aromatic pigments; and Chem Abs CA 64, 19459g, Tallec et al, Selective reduction of some alkyl-substituted dinitrobenzenes at controlled potential. The reader is directed to these references for general guidance on synthesis of compounds within the scope of Formula I.
"Aryl" in the terms "aryl", "arylC,_6alkyl" and "arylCι-6alkoxy" typically means phenyl or naphthyl, preferably phenyl. "Heteroaryl" in the terms "heteroaryl" and "heteroarylC^alkyl" means an aromatic mono- or bicyclic 5-10 membered ring with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur. Examples of 'heteroaryl' include thienyl, pyrrolyl, furyl, imidazolyl, thiazolyl, pyrimidinyl, pyridyl, indolyl, benzimidazolyl, benzothiazolyl, quinolyl and isoquinolyl. "Heterocyclyl" in the terms "heterocyclyl" and "heterocyclylC|_ήalkyl" means a non-aromatic mono- or bicyclic 5-10 membered ring with up to five ring hetero atoms selected from nitrogen, oxygen and sulphur. Examples of 'heterocyclyl' include pyrrolidinyl, morpholinyl, piperidinyl, dihydropyridinyl and dihydropyrimidinyl. "Cycloalkyl" means a non-aromatic mono- or bicyclic 5-10 membered carbon ring. Examples of "cycloalkyl" include cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptyl and bicyclo[4.4.0]decyl.
Typical values for generic groups include: C,.6alkoxy for example methoxy, C,.6alkylthio for example methylthio, C,.6alkylamino for example methylamino, di-(C,.6alkyl)amino for example dime hylamino, Cι-6alkoxycarbonyl for example methoxycarbonyl or ethoxycarbonyl, C,.6aIkylcarbamoyl for example methylcarbamoyl, di- C,.6alkylcarbamoyl for example dimethylcarbamoyl,
C,.6aIkylsulphonyl for example methylsulphonyl, arylsulphonyl for example phenylsulphonyl, C,.6alkyIaminosulphonyl for example methylaminosulphonyl, di-(C,.calkyl)aminosulphonyl for example dimethylaminosulphonyl, cyanoC,.6alkyl for example cyanomethyl, hydroxyC,_6alkyl for example hydroxymethyl, aminoC,.6alkyl for example aminoethyl, C,.6alkanoylamino for example formamido and acetamido, C,_ 6alkoxycarbonylamino for example methoxycarbonylamino, C,_6alkanoyl for example formyl and acetyl, C,.6aIkanoyloxy for example acetoxy, C,.6alkyl for example methyl, ethyl, isopropyl or tert-butyl, halo for example fluoro, chloro or bromo, aryl for example phenyl, arylC,.6alkyl for example benzyl, aryloxy for example phenoxy and arylC,.6aIkoxy for example benzyloxy.
Any ring in R1 or R2 may be optionally substituted, for example by upto 3 substituents. Suitable substituents include hydrogen, hydroxy, C^alkoxy, mercapto, Cι_6alkylthio, amino, C|.6alkylamino, di-(C,.6alkyl)amino, carboxy, carbamoyl, C,.6alkylcarbamoyl, di-C^alkylcarbamoyl, C,_6alkylsulphonyl, arylsulphonyl,
C,.6alkylaminosulphonyl, di-(C,.f,alkyl)aminosulphonyl, nitro, cyano, cyanoC,.6alkyl, hydroxyC^alkyl, aminoC,.6alkyl. C,_6alkanoylamino, C,.6alkoxycarbonylamino, C|.6alkanoyl, C,.6alkanoyloxy, C,.6alkyl, halo and trifluoromethyl.
In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only and references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only. An analogous convention applies to other generic terms.
It is to be understood that, insofar as certain of the compounds of Formula I defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the property of inhibiting raf. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, inhibitory properties against raf may be evaluated using the standard laboratory techniques referred to hereinafter.
Particular values for R1 include hydroxy; hydroxyC,.6alkyl for example hydroxymethyl and hydroxyethyl; carboxy; carbamoyl; C|_6alkylcarbamoyl for example methylcarbamoyl and ethylcarbamoyk di-C,„6alkylcarbamoyl for example di-methylcarbamoyl, di-ethylcarbamoyl and N-ethyl-N-methylcarbamoyl; nitro; cyano; C,.6alkoxy for example methoxy, ethoxy, propoxy and isopropoxy; amino; C|.6alkylamino for example methylamino, ethylamino and propylamino; di-(C,_6alkyl)amino for example di-methylamino, di-ethylamino and N-ethyl-N-methylamino; and C,.6alkoxycarbonyl for example methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl.
Preferred values for R1 are hydroxy, amino, C,.6alkylamino, di-(C,_6alkyl)amino, C,.6alkoxy and Cι_6alkoxycarbonyl; more preferably hydroxy, methylamino, ethylamino, propylamino, di-methylamino, di-ethylamino and N-ethyl-N-methylamino. Preferred positions for substitution of R1 into the phenyl ring indicated in Formula I are 3, 4 and/or 5; more preferably 3; 4; 3,4 or 3,5. Favourably R1 is selected from 4-hydroxy; 4-dimethylamino; 3-methoxy; 3,5-dimethoxy; 3-methoxycarbonyl; and 4-hydroxy-3 -methoxy: of these 4-hydroxy is most preferred.
R2 is preferably hydrogen.
Preferred values for p in (R')pare 1-2, especially 1.
A preferred value for p in (R )p is 0.
Particular values for q are 0-3, 0-2 or 0-1. A preferred value for q is 0. R3 is preferably C,.3alkyl, more preferably methyl or ethyl and especially methyl.
R4 is preferably aryl, more preferably phenyl, more preferably monosubstituted phenyl and especially monosubstituted phenyl in the meta position, preferably with an electron withdrawing substituent group. Typical electron withdrawing groups include amino, C|_6alkylamino, di-(C,.6alkyl)amino, carboxy, Cι_6alkylsulphonyl, arylsulphonyl, nitro, cyano, halo, and trifluoromethyl; of these amino, C,.6alkylamino, di-(C,.6alkyl)amino, nitro, cyano and halo are preferred; more preferably di-(C,.6alkyl)amino; more preferably di-(C alkyl)amino; and especially any of di-methylamino, di-ethylamino and N-ethyl-N- methylamino.
Particular combinations of R1 and (CH2)q-R4 include: R1 (CH2)q-R4
4-hydroxy 3-dimethylaminophenyl
4-hydroxy cyclohexylethyl
4-hydroxy 3 ,4-dichlorophenylmethy 1
4-hydroxy bicyclo[2.2.1]hept-2-ylmethyl
4-dimethylamino 3 -dimethy laminophenyl
3 -methoxy 3-dimethylaminophenyl
3,5-dimethoxy 3-dimethylaminophenyl
3 -methoxycarbonyl 3 -dimethylaminopheny 1
4-hydroxy-3 -methoxy 3 -dimethy laminophenyl
and with respect to these combinations, R2 is preferably hydrogen and R1 is preferably methyl.
According to another aspect of the present invention there is provided an inhibitor of raf kinase of formula II:
Figure imgf000009_0001
wherein:
R1 and R2, which may be the same or different are selected from hydroxy, C,.6alkoxy, mercapto, C,.6alkylthio, amino, C,.6alkylamino, di-(C,.6alkyl)amino. carboxy, C,_6alkoxycarbonyl, carbamoyl, C,.6alkylcarbamoyl, di-C^alkylcarbamoyl, C,.6alkylsulphonyl, arylsulphonyl, C,.6alkylaminosulphonyl, di-(Cl.6alkyl)aminosulphonyl, nitro, cyano, cyano C,.6alkyl, hydroxyCι_6alkyl, amino C,.6alkyl, C,.6alkanoylamino, C,.6alkoxycarbonylamino, C,.6alkanoyl, C,.6alkanoyloxy, C,.6alkyl, halo, trifluoromethyl, aryl, arylC,.6alkyl, arylC,.6alkoxy, heteroaryl, heteroarylC,.6alkyl, heterocyclyl and heterocyclylC,.6alkyl; p, which may take the same or different values for R1 and R2, is 0-3, and when p is 2 or 3 each group may be the same or different; R3 is C alkyl; q is 0-4;
R5 is selected from hydroxy, C,.6alkoxy, mercapto, C,.6alkylthio, amino, C,.6alkylamino, di-(C,.6alkyl)amino, carboxy, C,.5alkoxycarbonyl, carbamoyl, C,_6alkylcarbamoyl, di-C,.6alkylcarbamoyl, C,.6alkylsulphonyl, arylsulphonyl, C,.6alkylaminosulphonyl, di-(C,.6alkyl)aminosulphonyl, nitro, cyano, cyanoC,.6alkyl, hydroxyC,.6alkyl, aminoC ,.6 alkyl, C,.6alkanoylamino, C,.6alkoxycarbonylamino, C,.6alkanoyl, C,.6alkanoyloxy, halo, and trifluoromethyl, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with the proviso that methyl 3-[5-(3-methoxycarbonylbenzamido)-2-methylphenyl]aminocarbonylbenzoate is excluded.
In another aspect a preferred individual compound of the invention is N-{5-|"2-(3-N,N- dimethylaminophenyl)acetylamino]-2-methylphenyl}-4-hydroxybenzamide or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
Typical and preferred values for (R')p, (R2)p, R3 and q in Formula II are as set herein in relation to Formula I. R5 is preferably an electron withdrawing group. Typical electron withdrawing groups include amino, C,.6alkylamino, di-(Cl.6alkyl)amino, carboxy, C,.6alkylsulphonyl, arylsulphonyl, nitro, cyano, halo, and trifluoromethyl; of these amino, C,.6alkylamino, di-(C,.6alkyl)amino, nitro, cyano and halo are preferred; more preferably di-(C,.6alkyl)amino; more preferably di-(C alkyl)amino; and especially any of di-methylamino, di-ethylamino and N-ethyl-N-methylamino. The excluded compound is known from German patent DE 2552609, Salle et al, Institut Francais du Petrole, Aromatic diester diamides.
Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in
Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 1 13-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard. et al., Journal of Pharmaceutical Sciences, 77. 285 (1988); and e) N. Kakeya, et al, Chem Pharm Bull, 32, 692 (1984).
In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include methoxymethyl and for hydroxy include acetyl.
Examples of pro-drugs include in vivo hydrolysable esters of a compound of the Formula I. An in vivo hydrolysable ester of a compound of the Formula I containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include Cι_6alkoxymethyl esters for example methoxymethyl, C,_ 6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3_ 8cycloalkoxycarbonyloxyC,.6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3- dioxolan-2-ylmethyl esters for example 5-methyl-l,3-dioxolan-2-ylmefhyl; and C,_
^alkoxycarbonyloxy ethyl esters for example 1 -methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
When the compound contains a basic moiety it may form pharmaceutically acceptable salts with a variety of inorganic or organic acids, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. A suitable pharmaceutically-acceptable salt of the invention when the compound contains an acidic moiety is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
In order to use a compound of the Formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti- oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame). Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents. Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol. aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.
Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.
Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30μm or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.
Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of raf kinase activity.
In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention. Compounds of this invention may be useful in combination with known anti-cancer and cytotoxic agents. If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate. Therefore in a further aspect, the present invention provides a compound of the
Formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body.
In yet a further aspect, the present invention provides a compound of the Formula I or N-[5- (3 -cyclohexy lpropiony lamino)-2-methy lpheny 1] -4-hydroxybenzamide, N- [5 -(3 - cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexylacety lamino)-2-methylpheny 1] -4-acetoxybenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, N-[5-(3- cy clohexy lpropionylamino)-2-methylpheny 1] -4-methoxy carbonylbenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]benzamide, N-[5-(3- cy clohexy lpropiony lamino)-2-methylphenyl] -4-acetoxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide, (hereinafter excluded compounds) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in treating a disease condition mediated by raf kinase. In yet a further aspect the present invention provides a method of treating a disease or medical condition mediated by raf kinase which comprises administering to a warm-blooded animal an effective amount of a compound of the Formula I or excluded compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
The present invention also provides the use of a compound of the Formula I or excluded compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof in the preparation of a medicament for use in a disease condition mediated by raf kinase.
Although the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of raf kinase. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents. The compounds of Formula I are especially useful in treatment of tumours having a high incidence of ras mutation, such as colon, lung, and pancreatic tumours. By the administration of a composition having one (or a combination) of the compounds of this invention, development of tumours in a mammalian host is reduced.
In yet a further aspect, the present invention provides a compound of the Formula I or excluded compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof in the preparation of a medicament for treating cancer.
In another aspect the present invention provides a process for preparing a compound of the Formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises: reacting a compound of the Formula III:
Figure imgf000017_0001
with a compound of the Formula IV
Figure imgf000018_0001
Formula IV or an activated derivative thereof, under standard amide bond forming conditions, wherein variable groups are as hereinbefore defined wherein any functional group is protected, if necessary, and: i. removing any protecting groups; ii. optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
Typically a carbodiimide coupling reagent is used in the presence of an organic solvent (preferably an anhydrous polar aprotic organic solvent) at a non-extreme temperature, for example in the region -10 to 40°, typically ambient temperature of about 20°C. Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
Specific examples of protecting groups are given below for the sake of convenience, in which "lower" as in, for example, lower alkyl signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.
A carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester- forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).
Examples of carboxy protecting groups include straight or branched chain C].ι alkyl groups (for example isopropyl, t-butyl); lower alkoxy lower alkyl groups (for example methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (for example 1 -methoxycarbonyloxyethyl, 1 -ethoxycarbonyloxy ethyl); aryl lower alkyl groups (for example benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for example trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (for example trimethylsilylethyl); and C -6alkenyl groups (for example allyl and vinylethyl).
Methods particularly appropriate for the removal of carboxy protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis. Examples of hydroxy protecting groups include lower alkyl groups
(for example t-butyl). lower alkenyl groups (for example allyl); lower alkanoyl groups (for example acetyl); lower alkoxycarbonyl groups (for example t-butoxycarbonyl); lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl lower alkoxycarbonyl groups (for example benzoyloxycarbonyl, rj-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl); tri lower alkylsilyl (for example trimethylsilyl, t-butyldimethylsilyl) and aryl lower alkyl (for example benzyl) groups.
Examples of amino protecting groups include formyl, aralkyl groups (for example benzyl and substituted benzyl, p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl. and triphenylmethyl); di-p-anisylmethyl and furylmethyl groups; lower alkanoyl (for example acetyl); lower alkoxycarbonyl (for example t-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl lower alkoxycarbonyl groups (for example benzyloxycarbonyl, r methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl; trialkylsilyl (for example trimethylsilyl and t-butyldimethylsilyl); alkylidene (for example methylidene); benzylidene and substituted benzylidene groups.
Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as p-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as o-nitrobenzyloxycarbonyl. The reader is referred to Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents. The reader is referred to Protective Groups in Organic Synthesis. 2nd Edition, by Green et al, published by John Wiley & Sons for general guidance on protecting groups.
The compound of Formula III may be prepared by reduction of the corresponding nitro compound of Formula V.
Figure imgf000020_0001
Typical reaction conditions include the use of ammonium formate in the presence of a catalyst (for example palladium on carbon) in the presence of an organic solvent (preferably a polar protic solvent), preferably with heating, for example to about 60°. Any functional groups are protected and deprotected as necessary. The compound of Formula V may be prepared by reaction of a compound of Formula
VI with a compound of Formula VII under suitable amide bond forming conditions.
Figure imgf000020_0002
Formula VI
Formula
Figure imgf000020_0003
Typical conditions include activating the carboxyl group of the compound of Formula VI for example by treatment with a halo reagent (for example oxalyl chloride) to form an acyl halide in an organic solvent at ambient temperature, then reacting the activated compound with the compound of Formula VII. Any functional groups are protected and deprotected as necessary.
The following biological assays, data and Examples serve to illustrate the present invention. Biological Assays
Standard methods for assaying raf activity are described by Alessi et al. in Methods in Enzymology Volume 255, 279-290. Particular methods are outlined below. a) Method for assaying raf activity by means of phosphorylation of MEK Add 2 units active raf enzyme to 2.7μg of Glutathione S-transferase MAP/ERK
Kinase (GST-MEK), prepared from E. coli by standard procedures, in 30μl of 50mM Tris- HC1 pH7.4, O.lmM Ethylene Glycol bis (β -Aminoethylether)NNNN-Tetra-acetic Acid (EGTA), lmg/ml Bovine Serum Albumin (BSA), ImM sodium vanadate, 0.03% Brij-35, 0.1% β-mercaptoethanol. Add lOμl of inhibitor in 0.1 % DMSO. Add lOμl of Mg Adenosine Triphosphate (ATP) mix (50mM Mg Acetate, 50μM ATP,lμCi γ33P ATP. Incubate at room temperature for 90 minutes, stop reaction by adding 20μl SDS sample buffer and load on Sodium Dodecyl Sulfate (SDS) polyacrylamide gel. Fix the gel, dry and expose to X-ray film or a phosphor imager screen overnight. Phosphorimager analysis allows quantification of the raf activity by measurement of the intensity of the signal from the 70KD GST-MEK band, thus allowing measurement of compound potency against raf. b) Method for assaying raf activity by means of activating MEK Method 1
Mix 0.1 units of raf to 0.5μg GST-MEK, 1.1 μg Glutathione S-Transferase Mitogen Activated Protein Kinase (GST-MAP kinase) and 17μg myelin basic protein in 30μl final volume of 50mM Tris-HCl pH7.4, O.lmM EGTA, lmg/ml BSA, ImM sodium vanadate, 0.03% Brij-35, 0.1% β-mercaptoethanol. Add lOμl of inhibitor in 0.1% DMSO. Add lOμl of
Mg ATP mix (50mM Mg acetate, 150uM ATP,lμCi γ 3P ATP. Incubate at room temperature for 90 minutes. Stop the reaction by adding 50μl 20% phosphoric acid. Capture onto P81 phosphocellulose paper (Whatman), wash in 0.5% phosphoric acid three times, dry and count by liquid scintillation. Method 2
Mix 0.02 units of raf to 0.65μg GST-MEK and 2.6μg GST-MAP kinase in 30μl final volume of buffer containing 50mM Tris-HCl pH7.4, O.lmM EGTA, lmg/ml BSA, ImM sodium vanadate, 0.03% Brij-35, 0.1% β-mercaptoethanol. Add lOμl of inhibitor in 0.1% DMSO. Add lOμl of Mg ATP mix (50mM Mg acetate, 1.25mM). Incubate for 60 minutes at room temperature. Transfer 4μl to 50μl of the same buffer containing 17μg myelin basic protein and add lOμl of 50mM Mg acetate,150μM ATP,lμCi γ33P ATP. Incubate at room temperature for 10 minutes. Stop the reaction by adding 50μl 20% phosphoric acid. Capture onto P81 phosphocellulose paper (Whatman), wash in 0.5% phosphoric acid three times, dry and count by liquid scintillation.
The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:-
(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration; (ii) operations were carried out at ambient temperature, that is in the range
18-25°C and under an atmosphere of an inert gas such as argon;
(iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) C18 reverse phase silica separation;
(iv) yields are given for illustration only and are not necessarily the maximum attainable;
(v) the end-products of the Formula (1) have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and mass spectral techniques; chemical shift values were measured on the delta scale; the following abbreviations have been used: s, singlet; d, doublet; t or tr, triplet; m, multiplet; br, broad; (vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) or NMR analysis; (vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the Formula (1) were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture; and
(viii) the following abbreviations have been used:-
DMF dimethylformamide
HPLC high pressure liquid chromatography
MPLC medium pressure liquid chromatography
Example 1 N-[5-(2-Bicyclo|2.2.1]heDt-2-ylacetylamino)-2-methylphenyll-4-hvdroxybenzamide
A solution of N-(5-amino-2-methylphenyl)-4-hydroxybenzamide (133 mg) in dry DMF (0.5 ml) was added to 2-norbornanylacetic acid (77 mg) followed by a solution of l-(3-dimethylaminopropyl)-3-ethylcarbodimide hydrochloride (96 mg) in dry dichloromethane (3.0 ml). The reaction was stirred at ambient temperature for 5 hours. The solvents were removed by evaporation and the residue taken up into ethyl acetate (4.0 ml) and washed with water (3.0 ml). The aqueous layer was back extracted with ethyl acetate (4.0 ml) and the combined ethyl acetate extracts were evaporated to give 95 mg (53%) of the title product , shown to be 96% pure by HPLC using the following HPLC System:
Column HYPERSYL ODS 5μ; Flow Rate 1.5 ml/min
Dectector Wavelength 280λ; Oven Temperature 40 0C
Solvent A 1 mmol Et3N / H20; Solvent B 1 mmol Et3N / CH3CN Time 0-3 min 95%A:5%B
3-17 min gradient to 5%A:95%B
Retention Time 9.58 min.
The starting material was prepared as follows: A) Oxalyl chloride (0.5 ml) was added slowly to a stirred suspension of 4-acetoxybenzoic acid (1.09 g), dry dichloromethane (30 ml) and DMF (one drop). The mixture is stirred for two hours at ambient temperature. A solution of 2-methyl-5-nitroaniline (760 mg) and pyridine (2.0 ml) in dry dichloromethane was added over 15 minutes. The reaction mixture was stirred for a further 2 hours, washed with 5% aqueous acetic acid (2 x 25 ml), water (20 ml) and 5% aqueous sodium hydrogen carbonate solution. The organic extract was dried over magnesium sulphate, filtered and evaporated to dryness. The residue was crystallised from ethyl acetate (100 ml) to give 800 mgs (53%) of 4-acetoxy-N-(2-methyl-5- nitrophenyl)benzamide: melting point 207-208°C. Microanalysis: % Theory C 61.1, H 4.49, N 8.91 % Found C 61.0, H 4.3, N 8.8%.
NMR (DMSOd6) 2.3 (3H,s); 7.31 (2H,d), 7.56 (lH,d), 8.02 (3H,m); 8.47 (lH,d), 10.12 (lH,s) MH+ = 315
B) A stirred mixture of 4-acetoxy-N-(2-methyl-5-nitrophenyl)benzamide (500 mg), ammonium formate (1.0 g) and 10% palladium on carbon (25 mg) in methanol (10 ml) was heated at 60°C for 2 hours. The reaction mixture was cooled and filtered through diatomaceous earth (Celite®). The filtrate was evaporated to dryness and the residue triturated with water. The crude product was filtered from the aqueous solution and crystallised from methanol to give 140 mg (31% yield) of N-(5-amino-2-methylphenyl)-4- hy droxy benzamide . Melting point 277-278°C. Microanalysis: C14H14N202 requires C 69.4, H 5.8, N 11.6%; found C 69.1, H 5.8, N 11.5%. NMR (DMSOd6) 2.03(3H,s); 4.85(2H,s); 6.39(lH,dd); 6.61(lH,d); 6.85(3H,m); 7.82 (2H,d); 9.3(lH,s); 9.96 (lH,s) MH+ = 243
Example 2
N-f5-[2-(3,4-Dichlorophenyl)acetylamino1-2-methyIphenyl}-4-hvdroxybenzamide
The method of Example 1 was repeated using 3,4-dichlorophenylacetic acid (0.5 mmoles). The reaction mixture was evaporated and the residue taken up in ethyl acetate (4 ml), washed with 1M hydrochloric acid (3.0 ml) and water (3.0 ml). The ethyl acetate extract was evaporated to give the desired product, 132mg (68%), shown to be 92% pure by HPLC. NMR (DMSO-d6) δ: 2.23 (s, 3FI), 3.73 (s, 2H), 6.93 (d, 2H) 7.23 (d, 1H), 7.35-7.46 (m, 2H), 7.60-7.70 (m, 3H), 7.92 (d, 2H), 9.60 (s, 1H), 10.08 (s, 1H), 10.19 (s, 1H).
Example 3 N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl|-4-hvdroxybenzamide
N-(5-Amino-2-methylphenyl)-4-hydroxybenzamide (85 mg) was added to a stirred solution of 3-dimethylaminobenzoic acid (89 mg) in dry DMF (0.5 ml) followed by a solution of 1 -(3 -dimethy laminopropyl)-3-ethylcarbodiimide hydrochloride (103 mg) in dry dichloromethane (3 ml) and 4-dimefhylaminopyridine (131 mg). The reaction was stirred at ambient temperature under argon for 18 hours. The reaction mixture was purified by MPLC on silica eluting in turn with 50%, 60% and 70% ethyl acetate in isohexane to give 17 mg (1 1%) of the title product.
Microanalysis: % Theory C 68.6, H 5.8, N 10.3 (0.2 CH2C12) % Found C 68.1, H 5.7, N 10.9 NMR data (DMSO d6) δ 2.17 (s, 3H); 2.96 (s, 6H); 6.80 - 6.95(m, 3H); 7.15 - 7.35 (m, 4H); 7.58 (dd, 1H); 7.79 (d, 1H); 7.87 (d, 2H); 9.62 (s, 1H), 9.95(s, lH),10.10(s, 1H), Mff = 390.
Example 4 Pharmaceutical compositions:
The following illustrate representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:
(a) Tablet I mg/tablet
Compound X 100
Lactose Ph.Eur 182.75
Croscarmellose sodium 12.0
Maize starch paste (5% w/v paste) 2.25 Magnesium stearate 3.0
(b) Tablet II mg/tablet
Compound X 50
Lactose Ph.Eur 223.75 Croscarmellose sodium 6.0
Maize starch 15.0
Polyvinylpyrrolidone (5% w/v paste) 2.25
Magnesium stearate 3.0 (c) Tablet III mg/tablet
Compound X 1.0
Lactose Ph.Eur 93.25
Croscarmellose sodium 4.0 Maize starch paste (5% w/v paste) 0.75
Magnesium stearate 1.0
(d) Capsule mg/capsule Compound X 10 Lactose Ph.Eur 488.5
Magnesium 1.5
(e) Injection I (50 mg/ml) Compound X 5.0% w/v 1M Sodium hydroxide solution 15.0% v/v
0.1M Hydrochloric acid (to adjust pH to 7.6)
Polyethylene glycol 400 4.5% w/v
Water for injection to 100%
(f) Injection II (10 mg/ml)
Compound X 1.0% w/v
Sodium phosphate BP 3.6% w/v
0.1M Sodium hydroxide solution 15.0% v/v Water for injection to 100% (g) Injection III (lmg/ml, buffered to pH6)
Compound X 0.1% w/v
Sodium phosphate BP 2.26% w/v
Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v
Water for injection to 100%
(h) Aerosol I mg/ml
Compound X 10.0 Sorbitan trioleate 13.5
Trichlorofluoromethane 910.0
Dichlorodifluoromethane 490.0
(i) Aerosol II mg/ml Compound X 0.2
Sorbitan trioleate 0.27
Trichlorofluoromethane 70.0
Dichlorodifluoromethane 280.0
Dichlorotetrafluoroethane 1094.0
(j) Aerosol III mg/ml
Compound X 2.5
Sorbitan trioleate 3.38
Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0
Dichlorotetrafluoroethane 191.6 (k) Aerosol IV mg/ml
Compound X 2.5
Soya lecithin 2.7
Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0
Dichlorotetrafluoroethane 191.6
(1) Ointment ml
Compound X 40 mg Ethanol 300 μl
Water 300 μl
1 -Dodecylazacycloheptan-2-one 50 μl
Propylene glycol to 1 ml
Note
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.

Claims

Claims
1. A pharmaceutical composition comprising an inhibitor of raf kinase of the formula I
Figure imgf000030_0001
wherein:
R1 and R2, which may be the same or different are selected from hydroxy, C,.6alkoxy, mercapto, C,.6alkylthio, amino, C|.6alkylamino, di-(C,.6alkyl)amino, carboxy, C ^alkoxycarbonyl, carbamoyl, C,.6alkylcarbamoyl, di-C,.6alkylcarbamoyl, C^alkylsulphonyl, arylsulphonyl, C,.6alkylaminosulphonyl, di-(C,.6alkyl)aminosulphonyl, nitro, cyano, cyanoC,.f)alkyl, hydroxyC,.6alkyl, aminoC,.6alkyl, C,.6alkanoylamino, C^alkoxycarbonylamino, C,.6alkanoyl, C,.6alkanoyloxy, C,.6alkyl, halo, trifluoromethyl, aryl, arylC|.6alkyl, arylC,.6alkoxy, heteroaryl, heteroarylCU)alkyl, heterocyclyl and heterocyclylC,.6alkyl; p, which may take the same or different values for R1 and R2, is 0-3, and when p is 2 or 3 each group may be the same or different; R3 is C alkyl; q is 0-4;
R4 is aryl or cycloalkyl wherein R4 is optionally substituted with upto 3 substituents having any value defined for R' ; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier with the proviso that N-[5-(3-cyclohexyl- propionylamino)-2-methy lpheny 1] -4-hydroxybenzamide, _N- [5 -(3 - cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, _N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide. N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide, N-[5-(3- cyclohexylpropiony lamino)-2-methylphenyl] -2-hydroxybenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, N- [5 -(3 -cyclohexy lpropiony lamino)-2-methy lphenyljbenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide and N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide are excluded.
2. A pharmaceutical composition according to claim 1 wherein R3 is methyl.
3. A pharmaceutical composition according to either claim 1 or claim 2 wherein R4 is optionally substituted phenyl.
4. A pharmaceutical composition according to any one of claims 1 to 3 wherein p in (R2)p is 0.
5. A compound of the formula (I) as defined in any one of claims 1 to 4 or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof for use as a medicament.
6. A compound of the formula (I) as defined in any one of claims 1 to 4 or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof for use in treating a disease condition mediated by raf kinase.
7. An inhibitor of raf kinase of formula II:
Figure imgf000032_0001
wherein:
R1 and R2, which may be the same or different are selected from hydroxy, C,_6alkoxy, mercapto, C].6alkylthio, amino, C,.6alkylamino, di-(C,.6alkyl)amino, carboxy, C,.6alkoxycarbonyl, carbamoyl, C,.6alkylcarbamoyl, di-C,_6alkylcarbamoyl, C^alkylsulphonyl, arylsulphonyl, C,.6alkylaminosulphonyl, di-(C,.6alkyl)aminosulphonyl, nitro, cyano, cyanoC,.6alkyl, hydroxyC,.6alkyl, amino C1-6alkyl, C,.6alkanoylamino, C,.6alkoxycarbonylamino, C,.6alkanoyl, C^alkanoyloxy, C,.6alkyl, halo, trifluoromethyl, aryl, arylC,.6alkyl, arylC,.6alkoxy, heteroaryl, heteroarylC,.6alkyl, heterocyclyl and heterocyclylC,.6alkyl; p, which may take the same or different values for R1 and R2, is 0-3, and when p is 2 or 3 each group may be the same or different; R3 is C,.4 alkyl; q is 0-4; R5is selected from hydroxy, C,.6alkoxy, mercapto, Cι_6alkylthio, amino, C,.6alkylamino, di-(C,.6alkyl)amino, carboxy, C,.6alkoxycarbonyl, carbamoyl, C|.6alkylcarbamoyl, di-C,_6alkylcarbamoyl, C,.6alkylsulphonyl, arylsulphonyl, C,.6alkylaminosulphonyl, di-(C,.6alkyl)aminosulphonyl, nitro, cyano, cyanoC,.6alkyl, hydroxyC,.6alkyl, aminoC,.6alkyl, C,.6alkanoylamino, C^alkoxycarbonylamino, C,.6alkanoyl, C^alkanoyloxy, halo, and trifluoromethyl, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with the proviso that methyl 3-[5-(3-methoxycarbonylbenzamido)-2-methylphenylaminocarbonylbenzoate is excluded.
8. A compound which is N-[5-(2-bicyclo[2.2.1]hept-2-ylacetylamino)-2-methylphenyl]-4-hydroxybenzamide; N-{5-[2-(3,4-dichlorophenyl)acetylamino]-2-methylphenyl}-4-hydroxybenzamide; N-[5-(3-dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; or N-{5-[2-(3-NJN-dimethylaminophenyl)acetylamino]-2-methylphenyl}-4-hydroxybenzamide; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
9. Use of a compound of the formula (I) as defined in any one of claims 1 to 4 or N-[5- (3 -cyclohexy lpropiony lamino)-2-methy lphenyl] -4-hydroxybenzamide, N- [5 -(3 - cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, N-[5-(3- cyclohexy lpropiony lamino)-2-methy lphenyl] -4-methoxycarbony lbenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, N-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]benzamide, N-[5-(3- cyclohexy lpropiony lamino)-2-methy lphenyl] -4-acetoxybenzamide or N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically-acceptable salt thereof or an in vivo hydrolysable ester thereof in the preparation of a medicament for treating a disease or medical condition mediated by raf kinase.
10. Use of a compound of the formula (I) as defined in any one of claims 1 to 4 or N-[5- (3 -cyclohexy lpropiony lamino)-2-methylpheny 1] -4-hydroxybenzamide, N- [5 -(3 - cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- cyclohexylpropiony lamino)-2-methy lphenyl] -4-aminobenzamide, _N- [5 -(3 - cyclohexy lpropionylamino)-2-methylpheny 1] -4-nitrobenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, N-[5-(3- cyclohexy lpropionylamino)-2-methylpheny 1] -3 -hydroxybenzamide, N- [5 -(3 -cyclohexy lpropionylamino)-2-methy lpheny l]benzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide or N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically- acceptable salt thereof or an in vivo hydrolysable ester thereof in the preparation of a medicament for treating cancer.
11. A method of treating a disease or medical condition mediated by raf kinase comprising administering to a warm-blooded animal an effective amount of a compound of the formula (I) as defined in any one of claims 1 to 4 or N-[5-(3-cyclohexylpropionylamino)-2- methylphenyl]-4-hydroxybenzamide, N-[5-(3-cyclopentylpropionylamino)-2-methylphenyl]- 4-acetoxybenzamide, N-[5-(3-phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4-cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(2- cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide, N-[5-(3- cyclohexy lpropiony lamino)-2-methylphenyl] -2-hydroxybenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, N- [5 -(3 -cyclohexy lpropionylamino)-2-methy lpheny ljbenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide or N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide, or a pharmaceutically-acceptable salt thereof.
12. A method of providing a raf kinase inhibitory effect comprising administering to a warm- blooded animal an effective amount of a compound of the formula (I) as defined in any one of claims 1 to 4 or N- [5 -(3 -cyclohexy lpropiony lamino)-2-methylphenyl] -4-hydroxybenzamide, N-[5-(3-cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide. N-[5-(3- phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(4- cyclohexylbutyrylamino)-2-methy lphenyl] -4-acetoxybenzamide, N- [5 -(2- cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, N-[5-(3- cy clohexy lpropiony lamino)-2-methy lphenyl] -4-nitrobenzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide. N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide. N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide,
N- [5 -(3 -cyclohexy lpropiony lamino)-2-methylpheny 1] benzamide, N- [5 -(3 - cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide or N-[5-(3- cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide, or a pharmaceutically-acceptable salt thereof.
13. A process for preparing a compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises: reacting a compound of the Formula III:
Figure imgf000035_0001
with a compound of the Formula IV
O
(CH2)q R4
Formula IV or an activated derivative thereof , under standard amide bond forming conditions, wherein variable groups are as hereinbefore defined wherein any functional group is protected, if necessary, and: i. removing any protecting groups; ii. optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
PCT/GB1997/003102 1996-11-16 1997-11-12 Raf kinase inhibitors WO1998022103A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97912325A EP0941084A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors
AU49562/97A AU4956297A (en) 1996-11-16 1997-11-12 Raf kinase inhibitors
CA002267782A CA2267782A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors
JP52331698A JP2001504478A (en) 1996-11-16 1997-11-12 RAF kinase inhibitor
NO992336A NO992336D0 (en) 1996-11-16 1999-05-14 Raf kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623833.2A GB9623833D0 (en) 1996-11-16 1996-11-16 Chemical compound
GB9623833.2 1996-11-16

Publications (1)

Publication Number Publication Date
WO1998022103A1 true WO1998022103A1 (en) 1998-05-28

Family

ID=10803023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/003102 WO1998022103A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors

Country Status (8)

Country Link
EP (1) EP0941084A1 (en)
JP (1) JP2001504478A (en)
AU (1) AU4956297A (en)
CA (1) CA2267782A1 (en)
GB (1) GB9623833D0 (en)
NO (1) NO992336D0 (en)
WO (1) WO1998022103A1 (en)
ZA (1) ZA9710314B (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059960A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
WO2000021539A1 (en) * 1998-10-09 2000-04-20 Anadys Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
WO2000055120A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
EP1047418A1 (en) * 1997-12-22 2000-11-02 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
EP1056725A1 (en) * 1997-12-22 2000-12-06 Bayer Corporation Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
US6432949B1 (en) 1998-08-04 2002-08-13 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
US6455520B1 (en) 1998-09-25 2002-09-24 Astra Zeneca Ab Benzamide derivatives and their use as cytokine inhibitors
EP1017378B1 (en) * 1997-09-23 2002-12-11 AstraZeneca AB Amide derivatives for the treatment of diseases mediated by cytokines
WO2003056036A2 (en) * 2001-12-21 2003-07-10 The Wellcome Trust Genes
US6593333B1 (en) 1998-10-01 2003-07-15 Astrazeneca Ab Substituted anilino-quinazoline (or quinoline) compounds and use thereof
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
US6784174B1 (en) 1999-03-23 2004-08-31 Astrazeneca Ab Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
US6821965B1 (en) 1998-08-04 2004-11-23 Asterzeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
WO2005004863A1 (en) * 2003-07-11 2005-01-20 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
US6846827B1 (en) 1999-10-13 2005-01-25 Astrazeneca Ab Pyrimidine derivatives
WO2006007520A1 (en) * 2004-07-01 2006-01-19 Wisconsin Alumni Research Foundation Hydroxybenazamide compounds for treatment of cancer
US7008945B1 (en) 1999-03-17 2006-03-07 Astrazeneca Ab Amide derivatives
WO2006024836A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
WO2006067445A2 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006076706A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2007059157A1 (en) * 2005-11-14 2007-05-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7750154B2 (en) 2003-10-24 2010-07-06 Astrazeneca Ab Amide derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2011154846A3 (en) * 2010-05-11 2012-02-16 Mahesh Kandula 4, 6 -dibenzoylamino- 2 -methyl- pyrimidine derivatives and their use for the treatment of cancer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8143293B2 (en) 2007-04-20 2012-03-27 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
WO2013149194A1 (en) 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
US8940756B2 (en) 2012-06-07 2015-01-27 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9005475B2 (en) 2011-08-29 2015-04-14 Ticona Llc Aromatic amide compound
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
US9051514B2 (en) 2011-08-29 2015-06-09 Ticona Llc High flow liquid crystalline polymer composition
US9057016B2 (en) 2011-08-29 2015-06-16 Ticona Llc Melt polymerization of low melt viscosity liquid crystalline polymers
US9074133B2 (en) 2011-08-29 2015-07-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
US9096794B2 (en) 2011-08-29 2015-08-04 Ticona Llc High flow liquid crystalline polymer composition
US9102792B2 (en) 2013-02-22 2015-08-11 Ticona Llc High performance polymer composition with improved flow properties
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US10966966B2 (en) 2019-08-12 2021-04-06 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11185535B2 (en) 2019-12-30 2021-11-30 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US11266635B2 (en) 2019-08-12 2022-03-08 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11395818B2 (en) 2019-12-30 2022-07-26 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004170A1 (en) * 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004170A1 (en) * 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHTON ET AL.: "New Low-Density Lipoprotein Receptor Upregulators Acting via a Novel Mechanism", J. MED. CHEM., vol. 39, 1996, pages 3343 - 3356, XP002054111 *

Cited By (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
EP1017378B1 (en) * 1997-09-23 2002-12-11 AstraZeneca AB Amide derivatives for the treatment of diseases mediated by cytokines
US6498274B1 (en) 1997-09-23 2002-12-24 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
US6686467B2 (en) 1997-09-23 2004-02-03 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
EP1056725A4 (en) * 1997-12-22 2001-02-07 Bayer Ag Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1056725A1 (en) * 1997-12-22 2000-12-06 Bayer Corporation Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1047418A1 (en) * 1997-12-22 2000-11-02 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
EP1047418A4 (en) * 1997-12-22 2001-02-07 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
WO1999059960A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6956037B2 (en) 1998-05-15 2005-10-18 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6579872B1 (en) 1998-05-15 2003-06-17 Astrazeneca Ab Bezamide derivatives for the treatment of diseases mediated by cytokines
US6465455B1 (en) 1998-05-15 2002-10-15 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6432949B1 (en) 1998-08-04 2002-08-13 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
US7060700B2 (en) 1998-08-04 2006-06-13 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
US6821965B1 (en) 1998-08-04 2004-11-23 Asterzeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US6455520B1 (en) 1998-09-25 2002-09-24 Astra Zeneca Ab Benzamide derivatives and their use as cytokine inhibitors
US6593333B1 (en) 1998-10-01 2003-07-15 Astrazeneca Ab Substituted anilino-quinazoline (or quinoline) compounds and use thereof
US6716847B2 (en) 1998-10-01 2004-04-06 Astrazeneca Ab Substituted anilino-quinoline compounds and use thereof
WO2000021539A1 (en) * 1998-10-09 2000-04-20 Anadys Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
US6194399B1 (en) 1998-10-09 2001-02-27 Scriptgen Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6794380B2 (en) 1999-03-17 2004-09-21 Astrazeneca Ab Amide derivatives
JP2002539187A (en) * 1999-03-17 2002-11-19 アストラゼネカ アクチボラグ Amide derivatives
CN100352804C (en) * 1999-03-17 2007-12-05 阿斯特拉曾尼卡有限公司 Amide derivatives
WO2000055120A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
US7442704B2 (en) 1999-03-17 2008-10-28 Astrazeneca Ab Amide derivatives
US7008945B1 (en) 1999-03-17 2006-03-07 Astrazeneca Ab Amide derivatives
US7332483B2 (en) 1999-03-17 2008-02-19 Astrazeneca Ab Amide derivatives
US6548514B1 (en) 1999-03-17 2003-04-15 Astrazeneca Ab Amide derivatives
US6784174B1 (en) 1999-03-23 2004-08-31 Astrazeneca Ab Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
US6846827B1 (en) 1999-10-13 2005-01-25 Astrazeneca Ab Pyrimidine derivatives
US8580497B2 (en) 2001-12-21 2013-11-12 The Wellcome Trust Methods for detection of the oncogenic T1796A B-Raf mutation
US7947819B2 (en) 2001-12-21 2011-05-24 The Wellcome Trust B-raf polynucleotides
WO2003056036A3 (en) * 2001-12-21 2003-12-31 Wellcome Trust Genes
WO2003056036A2 (en) * 2001-12-21 2003-07-10 The Wellcome Trust Genes
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7342037B2 (en) 2002-12-31 2008-03-11 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7666895B2 (en) 2002-12-31 2010-02-23 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2004064733A3 (en) * 2003-01-15 2004-12-29 Univ Texas The use of c-raf inhibitors for the treatment of neurodegenerative diseases
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US7691870B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
WO2005004863A1 (en) * 2003-07-11 2005-01-20 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US7750154B2 (en) 2003-10-24 2010-07-06 Astrazeneca Ab Amide derivatives
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2006007520A1 (en) * 2004-07-01 2006-01-19 Wisconsin Alumni Research Foundation Hydroxybenazamide compounds for treatment of cancer
WO2006024836A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
WO2006067445A2 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006067445A3 (en) * 2004-12-22 2006-09-14 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006076706A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
AU2006315467B2 (en) * 2005-11-14 2013-02-07 Curis, Inc. Bisamide inhibitors of hedgehog signaling
WO2007059157A1 (en) * 2005-11-14 2007-05-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
US8101610B2 (en) 2005-11-14 2012-01-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
US8143293B2 (en) 2007-04-20 2012-03-27 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
WO2011154846A3 (en) * 2010-05-11 2012-02-16 Mahesh Kandula 4, 6 -dibenzoylamino- 2 -methyl- pyrimidine derivatives and their use for the treatment of cancer
CN102933560A (en) * 2010-05-11 2013-02-13 科瑞塞尼生物科技有限公司 4,6-dibenzamido-2-methyl-pyridine derivatives and applications to cancer treatment
US10265258B2 (en) 2010-11-02 2019-04-23 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9763866B2 (en) 2010-11-02 2017-09-19 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9737469B2 (en) 2010-11-02 2017-08-22 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9730877B2 (en) 2010-11-02 2017-08-15 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US11806555B2 (en) 2010-11-02 2023-11-07 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US11298570B2 (en) 2010-11-02 2022-04-12 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9895301B2 (en) 2010-11-02 2018-02-20 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US10994157B2 (en) 2010-11-02 2021-05-04 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9005475B2 (en) 2011-08-29 2015-04-14 Ticona Llc Aromatic amide compound
US9096794B2 (en) 2011-08-29 2015-08-04 Ticona Llc High flow liquid crystalline polymer composition
US9074133B2 (en) 2011-08-29 2015-07-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
US9057016B2 (en) 2011-08-29 2015-06-16 Ticona Llc Melt polymerization of low melt viscosity liquid crystalline polymers
US9051514B2 (en) 2011-08-29 2015-06-09 Ticona Llc High flow liquid crystalline polymer composition
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
WO2013149194A1 (en) 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP3459565A1 (en) 2012-03-29 2019-03-27 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
USRE48731E1 (en) 2012-06-07 2021-09-14 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US8940756B2 (en) 2012-06-07 2015-01-27 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US9102792B2 (en) 2013-02-22 2015-08-11 Ticona Llc High performance polymer composition with improved flow properties
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US11344536B1 (en) 2019-08-12 2022-05-31 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11813251B2 (en) 2019-08-12 2023-11-14 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US10966966B2 (en) 2019-08-12 2021-04-06 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11266635B2 (en) 2019-08-12 2022-03-08 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11426390B2 (en) 2019-08-12 2022-08-30 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11433056B1 (en) 2019-08-12 2022-09-06 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11529336B2 (en) 2019-08-12 2022-12-20 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11534432B2 (en) 2019-08-12 2022-12-27 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11576904B2 (en) 2019-08-12 2023-02-14 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US11844788B1 (en) 2019-12-30 2023-12-19 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11395818B2 (en) 2019-12-30 2022-07-26 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11918564B1 (en) 2019-12-30 2024-03-05 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11793795B2 (en) 2019-12-30 2023-10-24 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11801237B2 (en) 2019-12-30 2023-10-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US11185535B2 (en) 2019-12-30 2021-11-30 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US11576903B2 (en) 2019-12-30 2023-02-14 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US11612591B2 (en) 2019-12-30 2023-03-28 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11850240B1 (en) 2019-12-30 2023-12-26 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11850241B1 (en) 2019-12-30 2023-12-26 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11896585B2 (en) 2019-12-30 2024-02-13 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11903933B2 (en) 2019-12-30 2024-02-20 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11911370B1 (en) 2019-12-30 2024-02-27 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Also Published As

Publication number Publication date
NO992336L (en) 1999-05-14
GB9623833D0 (en) 1997-01-08
AU4956297A (en) 1998-06-10
ZA9710314B (en) 1998-05-18
CA2267782A1 (en) 1998-05-28
EP0941084A1 (en) 1999-09-15
NO992336D0 (en) 1999-05-14
JP2001504478A (en) 2001-04-03

Similar Documents

Publication Publication Date Title
EP0941084A1 (en) Raf kinase inhibitors
US10414726B2 (en) Therapeutic agents
DE69921804T2 (en) BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKIN-MEDIATED DISEASES
JP5010917B2 (en) c-Kit Regulator and Method of Use
US6498274B1 (en) Amide derivatives for the treatment of diseases mediated by cytokines
JP4191825B2 (en) 5-aminoisoxazole derivatives
CN100410245C (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
TWI407962B (en) Quinazoline derivatives
BR112018004175B1 (en) PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, HER2 INHIBITOR AND ANTITUMOR AGENT CONTAINING SAID COMPOUND AND THERAPEUTIC USES OF SAID COMPOUND
KR20180105700A (en) 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (CHK1) inhibitors, and their preparation and application
WO2019052535A1 (en) Compound for inhibiting and degrading cdk
JP2009504626A (en) Amide derivatives
US6472435B1 (en) Anti-tumor agents
JP2011500603A (en) 5- (2-hydroxyphenyl) tetrazole as HSP90 inhibitor against cancer
US9550764B2 (en) Fused heterocyclic compounds and their use
CN1321116C (en) Novel azepane derivatives
JP3742593B2 (en) Farnesyltransferase inhibitors
US6346633B1 (en) Anti-tumuor agents
JPH0560469B2 (en)
WO2018159613A1 (en) Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound
WO2019119486A1 (en) Class of pyrimidine derivative kinase inhibitors
US20240124515A1 (en) Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer
RU2799006C2 (en) ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND
CN113527321A (en) Trifluoromethyl pyrazolo seven-membered ring compound, crystal structure and preparation method
AU2011325809A1 (en) Benzamide derivative with anticancer activity and preparation method and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997912325

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 334813

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2267782

Country of ref document: CA

Ref country code: CA

Ref document number: 2267782

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 523316

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09308173

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997912325

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997912325

Country of ref document: EP